규제 업데이트
2026년 9월 16일•3분 읽기
FDA Approves ANDA203048 for Clindamycin Phosphate Injection by Rising
The FDA granted approval for Rising’s clindamycin phosphate injection products (6, 12, and 18 mg/mL) under application ANDA203048.
규제 업데이트
2026년 9월 15일•3분 읽기
FDA Grants Labeling Approval for Olmesartan Medoxomil Tablets (ANDA 078276)
FDA has approved labeling for oral Olmesartan Medoxomil tablets (5 mg, 20 mg, 40 mg) under ANDA 078276 submitted by Rising; the products are listed as discontinued.